Seagen shared that the company’s Phase III trial of Adcetris (brentuximab vedotin) demonstrated significant improvements in the overall survival of patients diagnosed with advanced classical Hodgkin lymphoma.

Merck’s Keytruda (pembrolizumab) received a rejection from the U.S. Food and Drug Administration for each of six supplemental Biologics License Applications to update the dosing frequency of the checkpoint inhibitor to include every-six-weeks administration.

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Merck & Co. is driving forward in its quest to develop a premier immuno-oncology pipeline with the acquisition of Australia-based Viralytics Ltd. and its oncolytic immunotherapy treatments.

Merck & Co.’s Keytruda came up short in a pivotal study as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Merck announced that the company pulled its application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer from the European Medicines Agency.

Seattle Genetics and Takeda Pharmaceutical Company announced positive results from the Phase III ECHELON-1 clinical trial in previously untreated advanced classical Hodgkin lymphoma.

Six months after touting positive data from a Phase I/II combination study of Opdivo and Adcetris in patients with relapsed or refractory classical Hodgkin lymphoma at the American Society of Hematology, Bristol-Myers Squibb and Seattle Genetics are plowing forward into a Phase III trial.